OvaScience Reports Third Quarter 2015 Financial Results

CAMBRIDGE, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, today reported third quarter 2015 financial results
and highlighted recent accomplishments.

“The recent publication of the AUGMENT patient experiences highlighted
the clinical benefit of the treatment in patients with poor fertility
prognoses,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of
OvaScience. “We continue to adapt our commercial operations to reflect
rapid changes in the fertility market. Our high-quality, scalable
manufacturing and technical operations give us confidence in our ability
to expand into new territories, such as Europe and Japan, while building
a strong foundation for introducing our other treatments. We remain on
track to introduce our OvaPrime treatment this year through a
preceptorship program in at least one international region to evaluate
its potential in women with too few or no eggs. We also continue to
expect to communicate by year end a development pathway for OvaTure, our
next-generation, hormone-free approach to IVF.”

Third Quarter and Recent Highlights

  • AUGMENTSM Treatment Peer-Reviewed
    Publication Showed Statistically Significant Improvements in Embryo
    Selection and Transfer Compared to Standard IVF

    First
    published analysis comparing the AUGMENT treatment to standard IVF
    using an egg allocation method demonstrated statistically significant
    higher rates of embryo selection and transfer with the AUGMENT
    treatment based on standard embryo quality measures, including
    preimplantation genetic diagnosis/screening. Improved pregnancy rates
    with the AUGMENT treatment were also reported in the publication.
    These positive results were published in the Journal of
    Fertilization: In Vitro– IVF-Worldwide
    and presented at a recent
    scientific symposium. Additionally, physicians offering the AUGMENT
    treatment reported 20 babies born with the treatment to date. The
    AUGMENT treatment is not available in the United States.
  • Hosted Scientific Symposium for Healthcare Providers on Advances in
    Egg Health

    Participated in the American Society for
    Reproductive Medicine (ASRM) Annual Meeting and held a scientific
    symposium focused on educating clinicians on the importance of egg
    health and new advances in fertility. The event featured experts on
    the role of mitochondria for healthy embryogenesis and the potential
    of egg precursor (EggPCSM) cells for developing novel
    fertility treatments. In addition, a summary of the first published
    AUGMENT treatment patient experience was presented.
  • On Track to Introduce the OvaPrimeSM
    Treatment Through Preceptorship Program

    Company expects to
    meet goal of introducing the OvaPrime treatment to patients through a
    preceptorship program in at least one international region outside the
    United States by year end. This initial preceptorship program is a
    non-commercial training period in which physicians gain clinical
    experience using the OvaPrime treatment to replenish the ovarian
    reserve in women who make too few or no eggs. The Company expects
    physicians will share their initial patient experiences as clinically
    meaningful insights become available.
  • Advanced Development Plans for the OvaTureSM
    Treatment

    Finalizing plans for the further development of the
    OvaTure treatment, a next-generation fertility treatment designed to
    grow fresh, healthy eggs without the need for hormone injections.
    OvaScience still anticipates that by year end the Company will define
    its strategy for developing the OvaTure treatment outside the United
    States.

Third Quarter Financial Results

  • Net loss for the three months ended September 30, 2015 was $17.9
    million, or ($0.66) per share, as compared to net loss of $12.9
    million, or ($0.54) per share, for the three months ended September
    30, 2014. This included non-cash stock-based compensation expense of
    $3.7 million. The increase in net loss is primarily attributable to
    planned higher personnel costs, stock-based compensation, and costs
    associated with the launch of the AUGMENT treatment in certain
    international IVF clinics. Launch costs include legal and consulting
    services and establishment of lab-based operations, which will also
    support introductions of future fertility treatments.
  • Research and development expense for the three months ended September
    30, 2015 was $4.0 million, compared to $5.3 million for the same
    period in 2014. This decrease is primarily driven by a decrease of
    $0.8 million related to the stock-based compensation expense recorded
    in the prior year, including $1.1 million for Founders’ stock, which
    was fully expensed in the first quarter of 2015 and will not recur,
    and $0.4 million in certain collaboration agreements and research
    grants, which expired prior to the current period.
  • Selling, general and administrative expense for the three months ended
    September 30, 2015 was $12.9 million, as compared to $7.1 million for
    the same period in 2014. This increase was primarily a result of $2.6
    million for employee compensation and related benefits, including
    stock-based compensation expense driven by the hiring of additional
    personnel, $2.6 million of costs associated with the launch of the
    AUGMENT treatment and international growth, $0.4 million in facilities
    expenses, and $0.2 million in accounting, tax and other expenses.

At September 30, 2015, OvaScience had cash, cash equivalents and
short-term investments of $141.7 million.

Upcoming Events and Presentations

  • OvaScience Investor Day, December 17 in New York, NY

About OvaScience
OvaScience (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions outside of the United States. OvaScience is
developing the OvaPrimeSM treatment, which could increase a
woman’s egg reserve, and the OvaTureSM treatment, a potential
next-generation IVF treatment that could help a woman produce healthy,
young, fertilizable eggs without hormone injections. For more
information, please visit www.ovascience.com
and www.augmenttreatment.com
and connect with us on Twitter
and Facebook.

Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment and two fertility treatments in development, including
statements relating to our confidence in our ability to expand into new
territories, including Europe and Japan, our plans to introduce the
OvaPrime treatment this year through a preceptorship program, and our
plans to communicate a development pathway for the OvaTure treatment by
year end. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including risks related to: the possibility that international
IVF clinics that we work with may determine not to begin or continue
providing the AUGMENT treatment for commercial or other reasons; our
expectation that the AUGMENT treatment and OvaPrime treatment meet the
requirements of a class of products exempt from premarket review and
approval under applicable regulations in those countries where we have
launched or plan to introduce the AUGMENT treatment and plan to
introduce the OvaPrime treatment; the commercial ramp up of the AUGMENT
treatment, which we expect will depend upon continued use of the AUGMENT
treatment in our partner clinics in new and existing regions,
significant uptake in the UAE as a result of the recent coverage, and
other programs that include driving first-line use of the AUGMENT
treatment, and further results from ACE clinic experience as they become
available; the science underlying our treatment and treatments in
development (including the AUGMENT, OvaPrime and OvaTure treatments),
which is unproven; our ability to obtain regulatory approval where
necessary for our potential treatments; our ability to develop our
potential treatments, including the OvaPrime and OvaTure treatments, on
the timelines we expect, if at all; our ability to commercialize the
AUGMENT treatment and our potential treatments, including the OvaPrime
treatment, on the timelines we expect, if at all; as well as those risks
more fully discussed in the “Risk Factors” section of our most recently
filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K.
The forward-looking statements contained in this press release reflect
our current views with respect to future events. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our
view as of any date subsequent to the date hereof.

 
OvaScience, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
           
As of

September 30,
2015

December 31,
2014

Assets
Current assets:
Cash and cash equivalents $ 50,842 $ 6,414
Short-term investments 90,830 53,817
Prepaid expenses and other current assets 3,650 1,647
Total current assets 145,322 61,878
Property and equipment, net 6,717 3,367
Investment in joint venture 241
Restricted cash 527 197
Other long-term assets 130
Total assets $ 152,807 $ 65,572
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $ 4,156 $ 2,520
Accrued expenses and other current liabilities 5,707 7,654
Total current liabilities 9,863 10,174
Other non-current liabilities 358 73
Total liabilities 10,221 10,247
Total stockholders’ equity 142,586 55,325
Total liabilities and stockholders’ equity $ 152,807 $ 65,572
 
OvaScience, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share data)
 
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
2015   2014     2015   2014
Revenues $ 75 $     $ 120 $
Costs and expenses:
Costs of revenues 940 1,091
Research and development 3,998 5,325 13,766 14,511
Selling, general and administrative 12,909   7,074     37,022   15,133
Total costs and expenses 17,847   12,399     51,879   29,644
Loss from operations (17,772)   (12,399)     (51,759)   (29,644)
Interest income (expense), net 141 (25) 286 (109)
Other income, net 25 24 31 38
Loss from equity method investment (316)   (523)     (1,176)   (915)
Net loss $ (17,922)   $ (12,923)     $ (52,618)   $ (30,630)
Net loss per share—basic and diluted $ (0.66)   $ (0.54)     $ (1.95)   $ (1.38)
Weighted average number of shares used in net loss per share—basic
and diluted
27,267   23,766     27,020   22,192

###

Contacts

OvaScience
Investors
Theresa McNeely, 617-299-7356
EVP,
Chief Communications Officer
tmcneely@ovascience.com
or
Media
Cara
Mayfield, 617-714-9638
Director, Corporate Communications
cmayfield@ovascience.com

Alrededor de la web